Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 180

Sort by

Sort Order Select

Journal Articles

Phase 2 Study of Pegylated Interferon in Patients with Essential Thrombocytopenia and Polycythemia Vera: Final Analysis Focused on the Two Diseases

Lucia Masarova, Prithviraj Bose, Naveen Pemmaraju, Gautam Borthakur, Srdan Verstovsek, C. Cameron Yin, Keyur P. Patel, Hagop M. Kantarjian

Blood (2024) 144 (Supplement 1): 1807.

https://doi.org/10.1182/blood-2024-211674

Published: 2024

Journal Articles

IHP-102 Reduces Hypoxia-Induced Pain Behaviors in Townes SCD Mice

Kennedy N Goldsborough, Israel Almeida, Ashwin P. Patel, John Paderi, Vivien Sheehan

Blood (2024) 144 (Supplement 1): 1106.

https://doi.org/10.1182/blood-2024-210418

Published: 2024

Journal Articles

Age-Related Prognoses of Genetic Subtypes in B-Cell Acute Lymphoblastic Leukemia/Lymphoma (B-ALL): Insights from a Decade of National Data

Ting Zhou, Nicholas J. Short, Nitin Jain, Keyur P. Patel, Elias Jabbour, Hagop M. Kantarjian, L. Jeffrey Medeiros, Bryan Iorgulescu

Blood (2024) 144 (Supplement 1): 1456.

https://doi.org/10.1182/blood-2024-208340

Published: 2024

Journal Articles

A Multi-Site Break through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib (Trial In Progress)

Blood (2024) 144 (Supplement 1): 4265.2.

https://doi.org/10.1182/blood-2024-201582

Published: 2024

Journal Articles

BRAF -Mutated Acute Myeloid Leukemia (AML) Represents a Prognostically Poor Subgroup Enriched for Myelodysplasia-Related Subtypes and Distinct from Other RAS Pathway Mutant AML

Blood (2024) 144 (Supplement 1): 2921.

https://doi.org/10.1182/blood-2024-210110

Published: 2024

Journal Articles

Prognostic Significance of TP53 Mutations in Lymphoplasmacytic Lymphoma

Anath Lionel, Sherif Seif, Xiaowen Sun, Lei Feng, Lorenzo Gensini, Bria Gabriel, Lauren S. Lewis, Hima Bansal, Melody R. Becnel, Mahmoud R. Gaballa, Hans C. Lee, Oren Pasvolsky, Krina K. Patel, J Christine Ye, Keyur P. Patel, Donna M. Weber, Robert Z. Orlowski, Sheeba K. Thomas

Blood (2024) 144 (Supplement 1): 3024.

https://doi.org/10.1182/blood-2024-211193

Published: 2024

Journal Articles

Ketogenic Diet Enhances CAR T Cell Antitumor Function Via β-Hydroxybutyrate

Blood (2024) 144 (Supplement 1): 4.

https://doi.org/10.1182/blood-2024-208913

Published: 2024

Journal Articles

Proposed Use of the Microfluidic Impedance Red Cell Assay (MIRCA) to Identify Individuals with Sickle Cell Disease in Need of Second Line Therapies

Akshay A Patwardhan, Ashwin P. Patel, Solomon Oshabaheebwa, Christopher A. Delianides, Zoe Sekyonda, Erica N Evans, Abhinav K Pasupuleti, Lindsey Abel, Michael A. Suster, Pedram Mohseni, Umut Gurkan, Vivien Sheehan

Blood (2024) 144 (Supplement 1): 2216.

https://doi.org/10.1182/blood-2024-205913

Published: 2024

Journal Articles

Long-Term Therapy with GBT021601 and Moderate Chronic Transfusion Therapy Prevent the Development of Hyperalgesia

Justin J Yoo, Kennedy N Goldsborough, Britney Hernandez, Ashwin P. Patel, Vivien Sheehan

Blood (2024) 144 (Supplement 1): 2492.

https://doi.org/10.1182/blood-2024-208655

Published: 2024

Journal Articles

Evaluating Efficacy and Safety of Rapid-Manufactured CD5KO CART5 Cells in Preclinical Models of T Cell Malignancies

Ruchi P. Patel, Trang Vu, Dean Qian, Yunlin Zhang, Guido Ghilardi, Steven Yang, Stefan K. Barta, Nicholas A. Siciliano, Adam E. Snook, Marco Ruella

Blood (2024) 144 (Supplement 1): 4848.

https://doi.org/10.1182/blood-2024-210255

Published: 2024

Journal Articles

Rheological Comparison of Red Cells from Individuals with SCD Treated with Gene Therapy, Haploidentical Transplantation or Hydroxyurea

Britney Hernandez, Ashwin P. Patel, Erica N Evans, Jordan Zgodny, Stephen Gottschalk, Brandon M Triplett, Serena De Vita, Kirby Wallace, David C Shyr, Elizabeth O Stenger, Suhag Parikh, Akshay Sharma, Vivien Sheehan

Blood (2024) 144 (Supplement 1): 4956.

https://doi.org/10.1182/blood-2024-210578

Published: 2024

Journal Articles

A Large Cluster of Parvovirus B19 Aplastic Crisis in Children with Sickle Cell Disease in Atlanta, GA (Dec 2023- July 2024)

Jason N Payne, Grace Kalmus, Ashwin P. Patel, Amy Tang, Marianne Yee, Beatrice E Gee

Blood (2024) 144 (Supplement 1): 3896.

https://doi.org/10.1182/blood-2024-212147

Published: 2024

Journal Articles

Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up

Jayastu Senapati, Hagop M. Kantarjian, Edward Ayoub, Akhil Jain, Tapan M. Kadia, Courtney D. DiNardo, Naval Daver, Fadi G. Haddad, Naveen Pemmaraju, Nicholas J. Short, Maro Ohanian, Musa Yilmaz, Keyur P. Patel, Mark Brandt, Sherry Pierce, Guillermo Garcia-Manero, Farhad Ravandi, Gautam Borthakur

Blood (2024) 144 (Supplement 1): 1513.

https://doi.org/10.1182/blood-2024-211599

Published: 2024

Journal Articles

Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML

Blood (2024) 144 (Supplement 1): 4263.

https://doi.org/10.1182/blood-2024-204296

Published: 2024

Journal Articles

Genomic Profiling of T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL) for Identification of Driver Aberrations Using Combined Next Generation Sequencing and Optical Genome Mapping in Clinical Diagnostic Laboratory

Iman Sarami, Ruchi Singhal, Mark Routbort, Koji Sasaki, Daniel Domogala III, Gokce A. Toruner, Shibu Ninan, Nitin Jain, Keyur P. Patel, Elias Jabbour, Hagop M. Kantarjian, Carlos E. Bueso-Ramos, L. Jeffrey Medeiros, Raja Luthra, Guilin Tang, Rashmi Kanagal-Shamanna

Blood (2024) 144 (Supplement 1): 4224.

https://doi.org/10.1182/blood-2024-211561

Published: 2024

Journal Articles

Methods to Assess the Impact of Combined Pharmacologic and Transfusion Therapies on Red Cell Deformability

Abhinav K Pasupuleti, Akshay A Patwardhan, Ashwin P. Patel, Solomon Oshabaheebwa, Christopher A. Delianides, Zoe Sekyonda, Erica N Evans, Lindsey Abel, Michael A. Suster, Pedram Mohseni, Umut Gurkan, Vivien Sheehan

Blood (2024) 144 (Supplement 1): 7510.

https://doi.org/10.1182/blood-2024-207680

Published: 2024

Journal Articles

CD5-Deleted Chimeric Antigen Receptor Cells (Senza5™ CART5) to Enhance Immunotherapy Against T-Cell Non-Hodgkin Lymphoma: A First-in-Human Phase I Clinical Trial

Blood (2024) 144 (Supplement 1): 7221.

https://doi.org/10.1182/blood-2024-201063

Published: 2024

Journal Articles

Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3038.

https://doi.org/10.1182/blood-2024-206042

Published: 2024

Journal Articles

Survival Benefits of Complete Cytogenetic Response in Patients with Newly Diagnosed Myelodysplastic Syndrome

Roberta Santos Azevedo, Hagop M. Kantarjian, Elias Jabbour, Rashmi Kanagal-Shamanna, Kelly S. Chien, Danielle Hammond, Samuel Urrutia, Carlos E. Bueso-Ramos, Keyur P. Patel, Guillermo Montalban-Bravo, Nicholas J. Short, Naval Daver, Gautam Borthakur, Tapan M. Kadia, William G. Wierda, Guillermo Garcia-Manero, Koji Sasaki

Blood (2024) 144 (Supplement 1): 6727.

https://doi.org/10.1182/blood-2024-201864

Published: 2024

Journal Articles

Overcoming the Lack of CD2:CD58 Costimulation in Chimeric Antigen Receptor T-Cell Immunotherapies

Alberto Carturan, Mathew G. Angelos, Raymone Pajarillo, Jesse Rodriguez, Jaryse Harris, Yunlin Zhang, Ekta Singh, Andrew Lee, Ositadimma Ugwuanyi, Ruchi P. Patel, Puneeth Guruprasad, Jean Lemoine, Jong Hyun Cho, Patrizia Porazzi, Stephen J. Schuster, Marco Ruella

Blood (2024) 144 (Supplement 1): 504.

https://doi.org/10.1182/blood-2024-206061

Published: 2024

NARROW

Phase 2 Study of Pegylated Interferon in Patients with Essential Thrombocytopenia and Polycythemia Vera: Final Analysis Focused on the Two Diseases

IHP-102 Reduces Hypoxia-Induced Pain Behaviors in Townes SCD Mice

Age-Related Prognoses of Genetic Subtypes in B-Cell Acute Lymphoblastic Leukemia/Lymphoma (B-ALL): Insights from a Decade of National Data

A Multi-Site Break through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib (Trial In Progress)

BRAF -Mutated Acute Myeloid Leukemia (AML) Represents a Prognostically Poor Subgroup Enriched for Myelodysplasia-Related Subtypes and Distinct from Other RAS Pathway Mutant AML

Prognostic Significance of TP53 Mutations in Lymphoplasmacytic Lymphoma

Ketogenic Diet Enhances CAR T Cell Antitumor Function Via β-Hydroxybutyrate

Proposed Use of the Microfluidic Impedance Red Cell Assay (MIRCA) to Identify Individuals with Sickle Cell Disease in Need of Second Line Therapies

Long-Term Therapy with GBT021601 and Moderate Chronic Transfusion Therapy Prevent the Development of Hyperalgesia

Evaluating Efficacy and Safety of Rapid-Manufactured CD5KO CART5 Cells in Preclinical Models of T Cell Malignancies

Rheological Comparison of Red Cells from Individuals with SCD Treated with Gene Therapy, Haploidentical Transplantation or Hydroxyurea

A Large Cluster of Parvovirus B19 Aplastic Crisis in Children with Sickle Cell Disease in Atlanta, GA (Dec 2023- July 2024)

Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up

Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML

Genomic Profiling of T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL) for Identification of Driver Aberrations Using Combined Next Generation Sequencing and Optical Genome Mapping in Clinical Diagnostic Laboratory

Methods to Assess the Impact of Combined Pharmacologic and Transfusion Therapies on Red Cell Deformability

CD5-Deleted Chimeric Antigen Receptor Cells (Senza5™ CART5) to Enhance Immunotherapy Against T-Cell Non-Hodgkin Lymphoma: A First-in-Human Phase I Clinical Trial

Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma

Survival Benefits of Complete Cytogenetic Response in Patients with Newly Diagnosed Myelodysplastic Syndrome

Overcoming the Lack of CD2:CD58 Costimulation in Chimeric Antigen Receptor T-Cell Immunotherapies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only